Chronic wounds are a major source of patient morbidity and healthcare expenditure, with impaired tissue oxygenation recognized as a notable obstacle to successful repair. Supersaturated oxygen (SSO2) therapies have gained increasing traction as adjunctive treatments to improve the local wound environment and support th...
Saumya Tawakley, Malathi Kalluri, Uttam Kalluri et al.· Cardiology in Review· 0 citations
Atherosclerotic cardiovascular disease originates in childhood, and cumulative exposure to low-density lipoprotein cholesterol (LDL-C) is a major determinant of lifetime cardiovascular risk. Multiple professional societies have published guidelines for lipid screening, diagnosis, and management in pediatric populations...
Nhi D Nguyen, Tzvi Fishkin, A. Makaryus et al.· Cardiology in Review· 0 citations
We used the National Inpatient Sample from 2016 to 2022 to compare complete revascularization with culprit-only percutaneous coronary intervention in adults hospitalized with non-ST-elevation myocardial infarction and multivessel disease. Hospitalizations complicated by cardiogenic shock, cardiac arrest, coronary arter...
M. Elkasaby, A. Alanazi, W. Frishman et al.· Cardiology in Review· 1 citation
In 2025, the US Food and Drug Administration (FDA) removed its prior class-wide boxed warnings for menopausal hormone therapy (MHT), paving the way for increased clinical use. Menopause accelerates cardiovascular risk independently of chronological aging, manifesting as a 7.5% increase in carotid-femoral pulse wave vel...
Ashwin A. Pillai, Aryan Mehta, Shea-Lee Godin et al.· Cardiology in Review· 0 citations
Cardiorenal syndrome (CRS) represents a complex bidirectional interaction between the heart and kidneys whereby acute or chronic failure of one organ precipitates dysfunction in the other. CRS occurring in the setting of cardiogenic shock (CS), or CRS-CS, remains one of the most severe manifestations, contributing subs...
Chirag Mehta, Zola Wilkerson, Sarah A. Bhanushali et al.· Cardiology in Review· 0 citations
Osimertinib, a third-generation EGFR-TKI, is now the standard first-line treatment for EGFR-mutant non-small cell lung cancer and is increasingly given in the adjuvant setting for up to 3 years and in combination with chemotherapy. As exposure has lengthened and shifted toward curative-intent settings, its cardiac effe...
S. Gopu, A. Khader, S. Agrawal et al.· Cardiology in Review· 0 citations
An overview of the molecular biology and physiologic functions of cMyBPC is provided and its role in HCM, myocardial injury, and other forms of cardiovascular disease is examined.
Chinonso Asuzu, J. Catanzaro, Tzvi Fishkin et al.· Cardiology in Review· 0 citations
A systematic literature search was executed across PubMed, MEDLINE, Embase, and PsycINFO utilizing MeSH terms such as "type 2 diabetes mellitus," "cognitive decline," "dementia," "insulin resistance," "neuroinflammation," and "neuroprotection," to synthesize evidence across the mechanisms, biomarkers, and therapeutic a...
Alok Kumar Singh, Vennela Dunde, Maitri H Maurya et al.· Cardiology in Review· 0 citations
Selective aldosterone synthase inhibitors (ASIs), including baxdrostat and lorundrostat, target CYP11B2 while sparing cortisol synthesis, offering a novel strategy for resistant and uncontrolled hypertension. Yet existing meta-analyses have included nonselective agents or omitted the latest phase 3 data. We searched Pu...
N. Hammad, M. Elkasaby, A. Gadelmawla et al.· Cardiology in Review· 1 citation
This focused narrative review synthesizes contemporary evidence on the mechanistic, subclinical, and clinical links between PCOS and cardiovascular disease and examines how hyperandrogenism may contribute to insulin resistance and related abnormalities, including dyslipidemia, hypertension, metabolic dysfunction-associ...
M. Moore, R. Hirani, Samy Khessib et al.· Cardiology in Review· 0 citations
This review covers the management of PDA in adults, highlighting the pathophysiology, morphological classification, clinical presentation, and current approaches to closure, with transcatheter closure currently the preferred approach.
Anthony J. Kaywood, Alishah Ahmadi, W. Frishman· Cardiology in Review· 0 citations
Evidence on all 3 LA strain phases in ESUS through July 2026 supports subclinical atrial cardiomyopathy as an embolic substrate independent of atrial fibrillation.
Sangharsha Thapa, Sangam Shah, Pratik Fnu et al.· Cardiology in Review· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
